Psoriasis News and Research

Latest Psoriasis News and Research

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular (CV) disease. However, the degree to which psoriasis is associated with major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death has not been defined. Now, new research from the University of Pennsylvania School of Medicine has revealed an increased incidence of MACE in patients with severe psoriasis.

4 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Essential protein linked to TNF induced inflammation

SCIENTISTS have discovered an essential protein that controls inflammation induced by 'tumour necrosis factor' (TNF) - an important part of the body's defences against infection and a driver of cancer-associated inflammation, according to research published in Nature today (Wednesday).

31 Mar 2011

XTRAC laser therapy can offer relief to patients with severe psoriasis

PhotoMedex, Inc. announced today the implications of the preliminary findings of a current clinical trial being performed by John Y.M. Koo, M.D., professor and vice chairman, department of dermatology, University of California, San Francisco. Dr. Koo's experimental treatment protocol could change the lives of millions of people suffering from moderate to severe psoriasis.

30 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Isotechnika fourth quarter consolidated net loss increases to $2.42 million

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2010 and provided a review of the Company's operational and financial progress for 2010 and to the current date.

25 Mar 2011

Immune system misinterprets threats and attacks body's own cells and tissue

Many chronic diseases are the result of the body's immune system mistakenly perceiving that the body is under attack from foreign bodies. A counterattack is then launched - an inflammatory response meant to vanquish the intruder. In reality, the immune system has misinterpreted the threat and is actually attacking the body's own cells and tissue.

24 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

Anacor enters $30 million loan agreement

Anacor Pharmaceuticals announced today that it has entered into a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation to provide up to $30 million in capital. Anacor used $6.6 million to repay the remaining obligations under its loan agreement with Lighthouse Capital Partners and expects to use the remainder of the capital to fund development activities related to AN2690, AN2728 and AN2898.

21 Mar 2011

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharmaceuticals announced today that it has entered into a development agreement with Medicines for Malaria Venture to develop Anacor's compound AN3661 for the treatment of malaria.

18 Mar 2011

Researchers discover 3-D structure of key biological receptor

Researchers have solved the three-dimensional structure of a key biological receptor. The finding has the potential to speed drug discovery in many areas, from arthritis to respiratory disorders to wound healing, because it enables chemists to better examine and design molecules for use in experimental drugs.

16 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients.

14 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Psoriasis News and Research

Latest Psoriasis News and Research

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

Study reveals increased incidence of major adverse cardiac events in patients with severe psoriasis

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Essential protein linked to TNF induced inflammation

XTRAC laser therapy can offer relief to patients with severe psoriasis

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Isotechnika fourth quarter consolidated net loss increases to $2.42 million

Immune system misinterprets threats and attacks body's own cells and tissue

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

Anacor enters $30 million loan agreement

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Researchers discover 3-D structure of key biological receptor

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Researchers create protein molecule for new anti-inflammatory therapies

Idera reports $6.0 million net loss for fourth quarter 2010

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Psoriasis News and Research

Latest Psoriasis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in